Neovacs and Biosense Global LLC sign option agreement worth up to €65 million plus royalties for chinese development and commercial rights to IFNα kinoid for lupus and dermatomyositis

 – Neovacs receives an upfront fee and is eligible for additional milestone payments and double digit sales royalties 
 – Biosense receives option for development and commercial rights to IFNα Kinoid for lupus and dermatomyositis in China and other selected territories 

Paris, February 21, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has signed with BioSense Global LLC a commercial license option agreement for its IFNα Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.

Download pdf